Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Completed
Hoffmann-La Roche
Phase 3
1969-12-31
To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients.
Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with
psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of
etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in
treating psoriasis in patients without HIV infection by reducing skin involvement and
clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Completed
National Cancer Institute (NCI)
N/A
2000-05-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of acitretin may be an effective way to prevent
the recurrence or further development of skin cancer.
PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin
cancers in patients with at least two previously treated skin cancers who have undergone
organ transplantation.
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Completed
Alliance for Clinical Trials in Oncology
N/A
2000-05-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. The use of acitretin may be an effective way to prevent
the recurrence or further development of skin cancer.
PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin
cancers in patients with at least two previously treated skin cancers who have undergone
organ transplantation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
